• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Schweizer on olaparib plus bipolar androgen therapy in mCRPC


In this video, Michael Schweizer, MD, discusses the background, findings, and takeaways of the study, “Bipolar androgen therapy (BAT) plus Olaparib in men with metastatic castration-resistant prostate cancer (mCRPC),” presented recently at the 2021 European Society for Medical Oncology Annual Meeting. Schweizer is an associate professor in the division of medical oncology at the University of Washington and an associate professor in the clinical research division at the Fred Hutchinson Cancer Research Center, Seattle, Washington

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.